Corporate Update from TapImmune and Positive Phase II Data from ACT Biotech TapImmune Inc. (TPIV-OTC.BB), a developer of immunotherapeutics for cancer and infectious disease, yesterday ... Laura Swartz October 15, 2010 at 10:46 AM
